CORRECTION: Atlantic Equities Downgrades IDEXX Laboratories to Neutral, Maintains $600 Price Target - Rating Change Updated
Portfolio Pulse from Benzinga Newsdesk
Atlantic Equities analyst Steve Chesney has downgraded IDEXX Laboratories from Overweight to Neutral, while maintaining a $600 price target.
August 04, 2023 | 10:52 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
IDEXX Laboratories has been downgraded from Overweight to Neutral by Atlantic Equities, but the $600 price target remains unchanged.
The downgrade from Overweight to Neutral by Atlantic Equities suggests a less optimistic outlook for IDEXX Laboratories, which could negatively impact the stock's price in the short term. However, the maintained price target of $600 indicates that the analyst still sees value in the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100